Resolute Research: Regenerative medicine

June 24, 2021

ViaCyte, a regenerative medicine company based in San Diego, recently raised $45 million in Series E funding. Investors included Adage Capital Partners, Invus Group, Asymmetry Ventures, Artis Ventures, Bain Capital Sciences, and TPG Capital.

ViaCyte is working on delivering novel stem cell-derived cell replacement therapies as a cure for Type 1 diabetes as well as a next-generation treatment for insulin-requiring Type 2 diabetes. 

According to the Mayo Clinic, “Regenerative medicine is focused on developing and applying new treatments to heal tissues and organs and restore function lost due to aging, disease, damage or defects.” 

The regenerative medicine market is booming. This is due to several factors, including the growing rate of genetic disorders and chronic diseases, major technological advances in the field, and greater company investment. The global market in regenerative medicine is expected to reach $17.9 billion by 2025, according to Markets and Markets. That is up from $8.5 billion last year. This $11 billion jump shows that the regenerative medicine market is hot and only getting hotter.

What does this translate to in terms of data?

We found 1,110 regenerative medicine companies. The heatmap below shows areas of focus and funding amounts.

Regenerative medicine companies by tag and funding levels (data from Crunchbase)Regenerative medicine companies by tag and funding levels (data from Crunchbase)

 

When we drill down further and look into regenerative medicine companies focusing specifically on diabetes, we found 172 companies. The heatmap below shows these areas of focus along with funding amounts for the companies.

Regenerative medicine companies with diabetes focus by tag and funding levels (data from Crunchbase)Regenerative medicine companies with diabetes focus by tag and funding levels (data from Crunchbase)

 

We found 93 results for regenerative medicine and diabetes in the Clinical Trials dataset. Here’s a look at clinical trials in this specific area for the past five years:

Clinical trials for regenerative medicine and diabetes with start date between 2017 and 2021Clinical trials for regenerative medicine and diabetes with start date between 2017 and 2021

 

On the tech transfer front, we found 36 tech transfer opportunities related to regenerative medicine and diabetes. As the Sankey diagram below shows, most of these tech transfers were from Tel Aviv University and the University of Pittsburgh.

Tech transfers on regenerative medicine and diabetes by tag and organizationTech transfers on regenerative medicine and diabetes by tag and organization

 

Research across all of these databases was conducted quickly and efficiently using ResoluteAI’s Foundation. To talk to a real person about how Foundation can help your company or organization, please email us at info@resolute.ai or drop us a line using the link below.

Let's talk

Lesley Pink

Lesley Pink, our senior digital editor/writer, has written across a range of industries including artificial intelligence, actuarial science, government, law, and financial journalism. She's a fan of the serial comma and mint chocolate chip ice cream. And no, pink is not her favorite color. You can reach Lesley at lesley@resolute.ai.